| CAS NO: | 10405-02-4 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| 1g | 电议 |
| Molecular Weight (MW) | 427.96 |
|---|---|
| Formula | C25H30NO3.Cl |
| CAS No. | 10405-02-4 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 41 mg/mL (95.8 mM) |
| Water: 86 mg/mL (201 mM) | |
| Ethanol: 42 mg/mL (98.1 mM) | |
| SMILES | O=C(C(C1=CC=CC=C1)(O)C2=CC=CC=C2)O[C@@H]3C[C@H]([N+]45CCCC4)CC[C@H]5C3.[Cl-] |
| Synonyms | IP631; Trospium chloride, IP-631; IP 631; trade name Sanctura; Tropez OD; Trosec; Regurin; Flotros; Spasmex; Spasmoly. |
| In Vitro | In vitro activity: Trospium Chloride is a competitive muscarinic cholinergic receptor antagonist. Target: mAChR Trospium chloride is an antimuscarinic agent indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. |
|---|---|
| In Vivo | Trospium has pharmacologic properties that are distinct from other antimuscarinic agents. After oral administration, absorption of the hydrophilic trospium chloride is slow and incomplete. Peak plasma concentrations (Cmax) of approximately 4 ng/mL are reached 4-5 hours after administration of a 20 mg immediate-release preparation. The mean bioavailability is approximately 10% and decreases by concomitant food intake (to a mean of 26% of the fasting area under the plasma concentration-time curve [AUC]). Trospium chloride displays dose proportional increases in AUC and Cmax after a single dose within the clinically relevant dose range (20-60 mg). The mean volume of distribution is approximately 350-800 L. |
| Animal model | Mice PK model |
| Formulation & Dosage | 20-60 mg |
| References | Urol Clin North Am, 2006. 33(4): p. 465-73, viii. |
m.cnreagent.com